Email Us
View Reports

Bone Cancer Treatment Market

Bone Cancer Treatment Market Analysis - By Bone Cancer Type (Primary Bone Cancer and Secondary Bone Cancer), By Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy and Surgery), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Size, Share, Trends, Growth and Global Forecast to 2024

  • ID : 99660027  |  
  • Published : Feb-2019  |  
  • Region : Global  |  
  • Pages : 160   |  
  • Publisher : Mordor Intelligence

Bone Cancer Treatment Market  Size and Growth Rate:

According to the Research Report, the global bone cancer treatment market was valued at USD 62,865.6 million in 2018 and is estimated to reach USD 83,770.9 million in 2024, with a compound annual growth rate of around 4.93%.

Bone Cancer Treatment Market  Growth Drivers and Restraints:

Although it accounts for significantly less than 1% of all cancers, the bone cancer market is expected to grow steadily over the forecast period from 2016 to 2024. It is expected that this market growth will be driven by several factors, which include worldwide research and development, public awareness of bone cancer and other bone diseases, medical infrastructure development, and technological advances. Due to research and development practices, a number of drugs and preparations are under consideration and are expected to enter the market during the forecast period.

However, chemotherapeutic drugs approved for the treatment of bone cancer do not have an effective treatment regimen because they always vary according to the prevailing conditions and how the patient's body responds to the drug. The side effects, risk and limitations associated with treatment limit the growth of the global market for bone cancer medicines. Also, the low prevalence of the disease is the main obstacle to market growth, followed by the high cost of research and development, diagnosis and treatment.

Bone Cancer Treatment Market Regional Presence:

The global market is segmented according to geographies, such as North America, Europe, Asia-Pacific and the rest of the world. The North American region is the most dominant market in the world due to the rapid growth in bone cancer incidences and increasing interest in R & D for the treatment of bone tumors. In contrast, the Asia-Pacific region and the rest of the world regions are expected to be the most promising markets over the coming period, due to increased awareness of bone cancer, its chronic effects, and its treatments.

Some of the Prominent Companies leading the Global Bone Cancer Treatment Market Profiled in the Report are:

  • Amgen
  • Baxter
  • Bayer AG
  • Hikma Pharmaceuticals
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company

Detailed Segmentation of the Global Bone Cancer Treatment Market:

Bone Cancer Treatment Market - By Bone Cancer Type:

  • Primary Bone Cancer

    • Osteosarcoma
    • Chondrosarcoma
    • Ewing Tumour
    • Fibrosarcoma and Malignant Fibrous Histiocytoma
    • Giant Cell Tumour of Bone
    • Chordoma

  • Secondary Bone Cancer (Metastatic Bone Cancer)

Bone Cancer Treatment Market - By Treatment Type:

  • Chemotherapy

    • Doxorubicin
    • Cisplatin
    • Cyclophosphamide
    • Etoposide
    • Other Chemotherapies

  • Targeted Therapy

    • Denosumab
    • Imatinib

  • Radiation Therapy
  • Surgery

Bone Cancer Treatment Market - By Region:

  • North America

    • United States
    • Canada
    • Mexico

  • Europe

    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe

  • Asia-Pacific

    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific

  • Middle East & Africa

    • GCC
    • South Africa
    • Rest of Middle East & Africa

  • South America

    • Brazil
    • Argentina
    • Rest of South America


1. Study Deliverables

2. Study Assumptions

3. Scope of the Study




1. Market Overview

2. Market Drivers

1. Increasing Incidence of Bone Cancer

2. Increasing Government Initiatives for Bone Cancer Awareness

3. Market Restraints

1. Unavailability of Effective Treatment and Side Effects

2. High Cost of Cancer Therapies

4. Porter's Five Force Analysis

1. Threat of New Entrants

2. Bargaining Power of Buyers/Consumers

3. Bargaining Power of Suppliers

4. Threat of Substitute Products

5. Intensity of Competitive Rivalry


1. Bone Cancer Type

1. Primary Bone Cancer

1. Osteosarcoma

2. Chondrosarcoma

3. Ewing Tumour

4. Fibrosarcoma and Malignant Fibrous Histiocytoma

5. Giant Cell Tumour of Bone

6. Chordoma

2. Secondary Bone Cancer (Metastatic Bone Cancer)

2. Treatment Type

1. Chemotherapy

1. Doxorubicin

2. Cisplatin

3. Cyclophosphamide

4. Etoposide

5. Other Chemotherapies

2. Targeted Therapy

1. Denosumab

2. Imatinib

3. Radiation Therapy

4. Surgery

3. Geography

1. North America

1. US

2. Canada

3. Mexico

2. Europe

1. Germany

2. UK

3. France

4. Italy

5. Spain

6. Rest of Europe

3. Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South korea

6. Rest of Asia-Pacific

4. Middle East and Africa

1. GCC

2. South Africa

3. Rest of Middle East and Africa

5. South America

1. Brazil

2. Argentina

3. Rest of South America


1. Company Profiles

1. Amgen

2. Baxter

3. Bayer AG

4. Hikma Pharmaceuticals

5. Johnson & Johnson

6. Novartis AG

7. Pfizer Inc.

8. Recordati Group

9. Takeda Pharmaceutical Company

*List Not Exhaustive


Purchase this Market Research Report


Call us on : +1 888 709 8757

Drop us an email at :